Search Results

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will participate in the following investor conferences in June.

ORIC Pharmaceuticals, Inc. announced that on June 3, 2024, ORIC granted a total of 30,000 non-qualified stock options and 4,800 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2024.

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended March 31, 2024.

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the completion of the dose escalation portion of the Phase 1b trial of ORIC-114 in patients with advanced solid tumors with EGFR and HER2 exon 20 alterations or HER2 amplifications.

ORIC Pharmaceuticals, Inc. announced that on May 1, 2024, ORIC granted a total of 14,500 non-qualified stock options and 2,300 restricted stock units to two new non-executive employees who began their employment with ORIC in April 2024.

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will participate in the following investor conferences in April.

ORIC Pharmaceuticals, Inc. announced that on April 1, 2024, ORIC granted a total of 84,800 non-qualified stock options and 14,400 restricted stock units to two new non-executive employees who began their employment with ORIC in March 2024.

ORIC Pharmaceuticals, Inc. today announced two oral presentations on ORIC-944, a potent and selective allosteric inhibitor of PRC2, and presentation of a new discovery candidate, ORIC-613, an orally bioavailable, potent and selective PLK4 inhibitor, at the 2024 American Association for Cancer Research (AACR) Annual Meeting.

ORIC Pharmaceuticals, Inc., (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter and year ended December 31, 2023.

ORIC Pharmaceuticals, Inc. announced that on March 1, 2024, ORIC granted a total of 3,600 non-qualified stock options and 600 restricted stock units to one new non-executive employee who began their employment with ORIC in February 2024.